ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PHAT vs MNPR // DIVIDEND YIELD & FCF PAYOUT SAFETY

Phathom Pharmaceuticals Inc. (NASDAQ) VS. Monopar Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PHAT 2 — MNPR 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PHAT VS. MNPR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PHAT MNPR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 87.10% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -17.40% -17.60 MNPR /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -2.53% — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -0.10% — — TIE /net-margins <GO>
Revenue Growth (YoY) 180.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 PHAT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 36.7 35.2 +1.50 PHAT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $466.6M $472.0M -$5.4M MNPR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PHAT REV MNPR REV PHAT GROSS % MNPR GROSS % PHAT FCF MNPR FCF
FY 2025 $175.1M $46.8M 87.1% — -$167.0M -$12.2M
FY 2024 $55.3M $45.3M 85.6% — -$266.9M -$6.4M
FY 2023 $682.0K $24.7M — — -$137.6M -$7.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PHAT // BETA —
MNPR // BETA —